-
Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
-
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
-
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
-
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...
All articles
2015-03-25
Green light for Novartis drug “Jakavi” for rare blood cancer treatment
Novartis drug “Jakavi” has been approved by the European Commission for the therapy of rare blood cancer, polycythemia vera. It is the first approved targeted drug for treatment of this disease and it gives hope for patients unresponsive to standard therapy with hydroxyurea.... Read more
Tags drug , cancer , eu , Novartis , targeted therapy , approval
2015-03-12
Potential of clinical trials in CEE region
Clinical trials are one of the indispensable steps of drug development. They are especially crucial for the assessment of effectiveness and safety of a novel medication. The whole pharmaceutical industry, which is growing rapidly all over the world, is trying to find new regions characterized by attr... Read more
Tags pharmaceutical , clinical trials , drug , CEE , company
2015-02-17
Pierre Fabre initiates Phase IIa trials for a new drug for Schizophrenia
A French multinational company Pierre Fabre Pharmaceuticals has announced a start of Phase IIa clinical trials for a new selective antagonist of dopamine D3 receptor called F17464 in patients suffering from schizophrenia. The major aim is to determine the effectiveness and assess safety of the drug d... Read more
Tags clinical trials , drug , Pierre Fabre , schizophrenia , F17464
2013-03-20